We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase II trial demonstrates predictive role of oligoclonal B cells and fusion genes for response to Nivolumab in recurrent ovarian cancer, highlighting potential treatment strategies.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: